Both conventional and innovative biomedical approaches require cost-effective protein drugs with high therapeutic potency, improved bioavailability, biocompatibility, stability and pharmacokinetics. The growing longevity of the human population, the increasing incidence and prevalence of age-related diseases and the better comprehension of genetic-linked disorders prompt to develop natural and engineered drugs addressed to fulfill emerging therapeutic demands. Conventional microbial systems have been for long time exploited to produce biotherapeutics, competing with animal cells due to easier operation and lower process costs. However, both biological platforms exhibit important drawbacks (mainly associated to intracellular retention of the product, lack of post-translational modifications and conformational stresses), that cannot be overcome through further strain optimization merely due to physiological constraints. The metabolic diversity among microorganisms offers a spectrum of unconventional hosts, that, being able to bypass some of these weaknesses, are under progressive incorporation into production pipelines. In this review we describe the main biological traits and potentials of emerging bacterial, yeast, fungal and microalgae systems, by comparing selected leading species with well established conventional organisms with a long run in protein drug production.
Unconventional microbial systems for the cost-efficient production of high-quality protein therapeutics / Corchero, Jl; Gasser, B; Resina, D; Smith, W; Parrilli, Ermenegilda; Vázquez, F; Abasolo, I; Giuliani, M; Jäntti, J; Ferrer, P; Saloheimo, M; Mattanovich, D; Schwartz S., Jr; Tutino, MARIA LUISA; Villaverde, A.. - In: BIOTECHNOLOGY ADVANCES. - ISSN 0734-9750. - 31:2(2013), pp. 140-153. [10.1016/j.biotechadv.2012.09.001]
Unconventional microbial systems for the cost-efficient production of high-quality protein therapeutics.
PARRILLI, ERMENEGILDA;TUTINO, MARIA LUISA;
2013
Abstract
Both conventional and innovative biomedical approaches require cost-effective protein drugs with high therapeutic potency, improved bioavailability, biocompatibility, stability and pharmacokinetics. The growing longevity of the human population, the increasing incidence and prevalence of age-related diseases and the better comprehension of genetic-linked disorders prompt to develop natural and engineered drugs addressed to fulfill emerging therapeutic demands. Conventional microbial systems have been for long time exploited to produce biotherapeutics, competing with animal cells due to easier operation and lower process costs. However, both biological platforms exhibit important drawbacks (mainly associated to intracellular retention of the product, lack of post-translational modifications and conformational stresses), that cannot be overcome through further strain optimization merely due to physiological constraints. The metabolic diversity among microorganisms offers a spectrum of unconventional hosts, that, being able to bypass some of these weaknesses, are under progressive incorporation into production pipelines. In this review we describe the main biological traits and potentials of emerging bacterial, yeast, fungal and microalgae systems, by comparing selected leading species with well established conventional organisms with a long run in protein drug production.File | Dimensione | Formato | |
---|---|---|---|
corchero 2013 1-s2.0-S0734975012001516-main.pdf
solo utenti autorizzati
Descrizione: articolo principale
Licenza:
Accesso privato/ristretto
Dimensione
341.61 kB
Formato
Adobe PDF
|
341.61 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.